;PMID: 8157709
;source_file_782.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..45] = [t:0..45]
;1)sentence:[e:50..106] = [t:50..106]
;2)section:[e:110..161] = [t:110..161]
;3)section:[e:165..248] = [t:165..248]
;4)sentence:[e:252..550] = [t:252..550]
;5)sentence:[e:551..754] = [t:551..754]
;6)sentence:[e:755..950] = [t:755..950]
;7)sentence:[e:951..1164] = [t:951..1164]
;8)sentence:[e:1165..1325] = [t:1165..1325]
;9)sentence:[e:1326..1551] = [t:1326..1551]
;10)sentence:[e:1552..1690] = [t:1552..1690]
;11)section:[e:1694..1738] = [t:1694..1738]

;section 0 Span:0..45
;J Clin Endocrinol Metab  1994 Apr;78(4):842-6
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..6] Clin) (NNP:[7..17] Endocrinol)
        (NNP:[18..23] Metab) (CD:[25..29] 1994) (.:[30..37] Apr;78-LRB-)
        (CD:[37..39] 4-RRB-) (CD:[39..43] :842) (::[43..44] -) (CD:[44..45] 6)))

;sentence 1 Span:50..106
;H-ras mutations in human pituitary carcinoma metastases.
;[50..55]:gene-rna:"H-ras"
;[75..105]:malignancy:"pituitary carcinoma metastases"
(SENT
  (NP-HLN
    (NP (NN:[50..55] H-ras) (NNS:[56..65] mutations))
    (PP-LOC (IN:[66..68] in)
      (NP (JJ:[69..74] human)
         (JJ:[75..84] pituitary) (NN:[85..94] carcinoma)
         (NNS:[95..105] metastases)))
    (.:[105..106] .)))

;section 2 Span:110..161
;Pei L, Melmed S, Scheithauer B, Kovacs K, Prager D.
(SEC
  (FRAG (NNP:[110..113] Pei) (NNP:[114..116] L,) (NNP:[117..123] Melmed)
        (NNP:[124..126] S,) (NNP:[127..138] Scheithauer) (NNP:[139..140] B)
        (,:[140..141] ,) (NNP:[142..148] Kovacs) (NNP:[149..150] K)
        (,:[150..151] ,) (NNP:[152..158] Prager) (NNP:[159..161] D.)))

;section 3 Span:165..248
;Department of Medicine, Cedars-Sinai Medical Center-UCLA School of Medicine 
;90048.
(SEC
  (FRAG (NNP:[165..175] Department) (IN:[176..178] of) (NNP:[179..187] Medicine)
        (,:[187..188] ,) (NNP:[189..195] Cedars) (::[195..196] -)
        (NNP:[196..201] Sinai) (NNP:[202..209] Medical) (NNP:[210..216] Center)
        (::[216..217] -) (NNP:[217..221] UCLA) (NNP:[222..228] School)
        (IN:[229..231] of) (NNP:[232..240] Medicine) (CD:[242..247] 90048)
        (.:[247..248] .)))

;sentence 4 Span:252..550
;Molecular mechanisms of pituitary tumorigenesis were studied using Polymerase
; chain reaction-single stranded conformational polymorphism with DNA
;sequencing  to identify potential mutations in the ras protooncogenes and the
;tumor  suppressor gene p53 in invasive pituitary adenomas and carcinomas.
;[319..329]:gene-protein:"Polymerase"
;[450..453]:gene-rna:"ras"
;[477..503]:gene-rna:"tumor  suppressor gene p53"
;[507..534]:malignancy:"invasive pituitary adenomas"
;[539..549]:malignancy:"carcinomas"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[252..261] Molecular) (NNS:[262..272] mechanisms))
      (PP (IN:[273..275] of)
        (NP (JJ:[276..285] pituitary) (NN:[286..299] tumorigenesis))))
    (VP (VBD:[300..304] were)
      (VP (VBN:[305..312] studied)
        (NP-SBJ (-NONE-:[312..312] *))
        (S-MNR
          (NP-SBJ (-NONE-:[312..312] *))
          (VP (VBG:[313..318] using)
            (NP
              (NP
                (NML (NN:[319..329] Polymerase) (NN:[331..336] chain)
                     (NN:[337..345] reaction))
                (HYPH:[345..346] -)
                (ADJP (JJ:[346..352] single) (JJ:[353..361] stranded))
                (JJ:[362..376] conformational) (NN:[377..389] polymorphism))
              (PP (IN:[390..394] with)
                (NP (NN:[395..398] DNA) (NN:[399..409] sequencing))))
            (S-PRP
              (NP-SBJ (-NONE-:[409..409] *))
              (VP (TO:[411..413] to)
                (VP (VB:[414..422] identify)
                  (NP
                    (NP (JJ:[423..432] potential) (NNS:[433..442] mutations))
                    (PP-LOC (IN:[443..445] in)
                      (NP (DT:[446..449] the) (NN:[450..453] ras)
                          (NNS:[454..468] protooncogenes))))
                  (CC:[469..472] and)
                  (NP
                    (NP
                      (NP (DT:[473..476] the)
                        (NML (NN:[477..482] tumor) (NN:[484..494] suppressor))
                        (NN:[495..499] gene))
                      (NP (NN:[500..503] p53)))
                    (PP-LOC (IN:[504..506] in)
                      (NP
                        (NP
                          (ADJP-3 (JJ:[507..515] invasive))
                          (ADJP-2 (JJ:[516..525] pituitary))
                          (NNS:[526..534] adenomas))
                        (CC:[535..538] and)
                        (NP
                          (ADJP-3 (-NONE-:[538..538] *P*))
                          (ADJP-2 (-NONE-:[538..538] *P*))
                          (NNS:[539..549] carcinomas))))))))))))
    (.:[549..550] .)))

;sentence 5 Span:551..754
;Sequencing of  exons 5 through 8 of the p53 gene revealed no mutations, nor
;were mutations  detected in the N- or K-ras protooncogenes in four of the
;carcinomas and their  respective metastatic deposits.
;[566..583]:variation-location:"exons 5 through 8"
;[591..594]:gene-rna:"p53"
;[612..621]:variation-event:"mutations"
;[632..641]:variation-event:"mutations"
;[659..661]:gene-rna:"N-"
;[665..670]:gene-rna:"K-ras"
;[701..711]:malignancy:"carcinomas"
;[734..753]:malignancy:"metastatic deposits"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (NN:[551..561] Sequencing))
        (PP (IN:[562..564] of)
          (NP
            
            (NP
              (NML-1 (NNS:[566..571] exons))
              (CD:[572..573] 5))
            (PP (IN:[574..581] through)
              (NP
                (NML-1 (-NONE-:[581..581] *P*))
                (CD:[582..583] 8)))
            (PP (IN:[584..586] of)
              (NP (DT:[587..590] the) (NN:[591..594] p53) (NN:[595..599] gene))))))
      (VP (VBD:[600..608] revealed)
        (NP (DT:[609..611] no) (NNS:[612..621] mutations))))
    (,:[621..622] ,) (CC:[623..626] nor)
    (SINV (VBD:[627..631] were)
      (NP-SBJ-2 (NNS:[632..641] mutations))
      (VP (VBN:[643..651] detected)
        (NP-2 (-NONE-:[651..651] *))
        (PP-LOC (IN:[652..654] in)
          (NP (DT:[655..658] the)
            (NML
              (NML
                (NML
                   (NN:[659..660] N) (HYPH:[660..661] -)
                  (NML-3 (-NONE-:[661..661] *P*)))
                (NML-4 (-NONE-:[661..661] *P*)))
              (CC:[662..664] or)
              (NML
                (NML (NN:[665..666] K) (HYPH:[666..667] -)
                  (NML-3 (NN:[667..670] ras)))
                (NML-4 (NNS:[671..685] protooncogenes))))))
        (PP-LOC (IN:[686..688] in)
          (NP
            (NP (CD:[689..693] four))
            (PP (IN:[694..696] of)
              (NP
                (NP (DT:[697..700] the) (NNS:[701..711] carcinomas))
                (CC:[712..715] and)
                (NP (PRP$:[716..721] their) (JJ:[723..733] respective)
                   (JJ:[734..744] metastatic) (NNS:[745..753] deposits))))))))
    (.:[753..754] .)))

;sentence 6 Span:755..950
;Point mutations of H-ras however, were  identified in three distant
;metastatic pituitary tumor secondaries, but not in  their respective primary
;pituitary carcinomas, or in six invasive adenomas.
;[755..770]:variation-type:"Point mutations"
;[774..779]:gene-rna:"H-ras"
;[815..861]:malignancy:"distant metastatic pituitary tumor secondaries"
;[892..920]:malignancy:"primary pituitary carcinomas"
;[932..949]:malignancy:"invasive adenomas"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[755..760] Point) (NNS:[761..770] mutations))
      (PP (IN:[771..773] of)
        (NP (NN:[774..779] H-ras))))
    (VP
      (ADVP (RB:[780..787] however))
      (,:[787..788] ,) (VBD:[789..793] were)
      (VP
        (VP (VBN:[795..805] identified)
          (NP-1 (-NONE-:[805..805] *))
          (PP-LOC=2 (IN:[806..808] in)
            (NP (CD:[809..814] three)
               (JJ:[815..822] distant)
              (NML (JJ:[823..833] metastatic) (JJ:[834..843] pituitary)
                   (NN:[844..849] tumor))
              (NNS:[850..861] secondaries))))
        (,:[861..862] ,)
        (CONJP (CC:[863..866] but) (RB:[867..870] not))
        (VP
          (PP-LOC=2
            (PP (IN:[871..873] in)
              (NP (PRP$:[875..880] their) (JJ:[881..891] respective)
                 (JJ:[892..899] primary) (JJ:[900..909] pituitary)
                 (NNS:[910..920] carcinomas)))
            (,:[920..921] ,) (CC:[922..924] or)
            (PP (IN:[925..927] in)
              (NP (CD:[928..931] six)
                 (JJ:[932..940] invasive) (NNS:[941..949] adenomas)))))))
    (.:[949..950] .)))

;sentence 7 Span:951..1164
;Two  of the mutations included a G to C substitution at codon 12, and a G to
;A  substitution at codon 18, resulting in a glycine to arginine, and an
;alanine to  threonine change at these amino acids, respectively.
;[963..972]:variation-event:"mutations"
;[984..985]:variation-state-original:"G"
;[989..990]:variation-state-altered:"C"
;[991..1003]:variation-type:"substitution"
;[1007..1015]:variation-location:"codon 12"
;[1023..1024]:variation-state-original:"G"
;[1028..1029]:variation-state-altered:"A"
;[1031..1043]:variation-type:"substitution"
;[1047..1055]:variation-location:"codon 18"
;[1072..1079]:variation-state-original:"glycine"
;[1083..1091]:variation-state-altered:"arginine"
;[1100..1107]:variation-state-original:"alanine"
;[1112..1121]:variation-state-altered:"threonine"
(SENT
  (S
    (NP-SBJ
      (NP (CD:[951..954] Two))
      (PP (IN:[956..958] of)
        (NP (DT:[959..962] the) (NNS:[963..972] mutations))))
    (VP (VBD:[973..981] included)
      (NP
        (NP
          (NP (DT:[982..983] a)
            (NML
              (NML (NN:[984..985] G))
              (PP (TO:[986..988] to)
                (NP (NN:[989..990] C))))
            (NN:[991..1003] substitution))
          (PP-LOC (IN:[1004..1006] at)
            (NP (NN:[1007..1012] codon) (CD:[1013..1015] 12))))
        (,:[1015..1016] ,) (CC:[1017..1020] and)
        (NP
          (NP (DT:[1021..1022] a)
            (NML
              (NML (NN:[1023..1024] G))
              (PP (TO:[1025..1027] to)
                (NP (NN:[1028..1029] A))))
            (NN:[1031..1043] substitution))
          (PP-LOC (IN:[1044..1046] at)
            (NP (NN:[1047..1052] codon) (CD:[1053..1055] 18)))))
      (,:[1055..1056] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[1056..1056] *))
        (VP (VBG:[1057..1066] resulting)
          (PP-CLR (IN:[1067..1069] in)
            (NP
              (NP (DT:[1070..1071] a)
                (NML
                  (NML
                    (NML
                      (NML (NN:[1072..1079] glycine))
                      (PP (TO:[1080..1082] to)
                        (NP (NN:[1083..1091] arginine))))
                    (NML-1 (-NONE-:[1091..1091] *P*)))
                  (,:[1091..1092] ,) (CC:[1093..1096] and)
                  (NML
                    (NML
                      (NML (DT:[1097..1099] an) (NN:[1100..1107] alanine))
                      (PP (TO:[1108..1110] to)
                        (NP (NN:[1112..1121] threonine))))
                    (NML-1 (NN:[1122..1128] change)))))
              (PP-LOC (IN:[1129..1131] at)
                (NP (DT:[1132..1137] these) (JJ:[1138..1143] amino)
                    (NNS:[1144..1149] acids)))))
          (,:[1149..1150] ,)
          (ADVP (RB:[1151..1163] respectively)))))
    (.:[1163..1164] .)))

;sentence 8 Span:1165..1325
;A third mutation involved a  single base pair (adenine) deletion in codon 3
;of H-ras which causes a frame  shift, resulting in a termination signal at
;codon 19.
;[1173..1181]:variation-event:"mutation"
;[1212..1219]:variation-state-original:"adenine"
;[1221..1229]:variation-type:"deletion"
;[1233..1240]:variation-location:"codon 3"
;[1244..1249]:gene-rna:"H-ras"
;[1265..1277]:variation-type:"frame  shift"
;[1316..1324]:variation-location:"codon 19"
(SENT
  (S
    (NP-SBJ (DT:[1165..1166] A) (JJ:[1167..1172] third)
            (NN:[1173..1181] mutation))
    (VP (VBD:[1182..1190] involved)
      (NP
        (NP
          (NP (DT:[1191..1192] a) (JJ:[1194..1200] single)
            (NML (NN:[1201..1205] base) (NN:[1206..1210] pair)
              (PRN (-LRB-:[1211..1212] -LRB-)
                (NP (NN:[1212..1219] adenine))
                (-RRB-:[1219..1220] -RRB-)))
            (NN:[1221..1229] deletion))
          (PP-LOC (IN:[1230..1232] in)
            (NP
              (NP (NN:[1233..1238] codon) (CD:[1239..1240] 3))
              (PP (IN:[1241..1243] of)
                (NP (NN:[1244..1249] H-ras))))))
        (SBAR
          (WHNP-1 (WDT:[1250..1255] which))
          (S
            (NP-SBJ-1 (-NONE-:[1255..1255] *T*))
            (VP (VBZ:[1256..1262] causes)
              (NP (DT:[1263..1264] a)
                 (NN:[1265..1270] frame) (NN:[1272..1277] shift))
              (,:[1277..1278] ,)
              (S-ADV
                (NP-SBJ (-NONE-:[1278..1278] *))
                (VP (VBG:[1279..1288] resulting)
                  (PP-CLR (IN:[1289..1291] in)
                    (NP
                      (NP (DT:[1292..1293] a) (NN:[1294..1305] termination)
                          (NN:[1306..1312] signal))
                      (PP-LOC (IN:[1313..1315] at)
                        (NP (NN:[1316..1321] codon) (CD:[1322..1324] 19))))))))))))
    (.:[1324..1325] .)))

;sentence 9 Span:1326..1551
;These results suggest that  point mutations in p53 and ras are not associated
;with pituitary tumorigenesis,  however, point mutations of the H-ras gene may
;be important in the formation and  or growth of pituitary metastases.
;[1354..1369]:variation-type:"point mutations"
;[1373..1376]:gene-rna:"p53"
;[1381..1384]:gene-rna:"ras"
;[1444..1459]:variation-type:"point mutations"
;[1467..1472]:gene-rna:"H-ras"
;[1530..1550]:malignancy:"pituitary metastases"
(SENT
  (S
    (NP-SBJ (DT:[1326..1331] These) (NNS:[1332..1339] results))
    (VP (VBP:[1340..1347] suggest)
      (SBAR (IN:[1348..1352] that)
        (S
          (S
            (NP-SBJ-1
              (NP (NN:[1354..1359] point) (NNS:[1360..1369] mutations))
              (PP (IN:[1370..1372] in)
                (NP (NN:[1373..1376] p53) (CC:[1377..1380] and)
                    (NN:[1381..1384] ras))))
            (VP (VBP:[1385..1388] are) (RB:[1389..1392] not)
              (VP (JJ:[1393..1403] associated)
                (NP-1 (-NONE-:[1403..1403] *))
                (PP-CLR (IN:[1404..1408] with)
                  (NP (JJ:[1409..1418] pituitary)
                      (NN:[1419..1432] tumorigenesis))))))
          (,:[1432..1433] ,)
          (S
            (ADVP (RB:[1435..1442] however))
            (,:[1442..1443] ,)
            (NP-SBJ
              (NP (NN:[1444..1449] point) (NNS:[1450..1459] mutations))
              (PP (IN:[1460..1462] of)
                (NP (DT:[1463..1466] the) (NN:[1467..1472] H-ras)
                    (NN:[1473..1477] gene))))
            (VP (MD:[1478..1481] may)
              (VP (VB:[1482..1484] be)
                (ADJP-PRD (JJ:[1485..1494] important))
                (PP (IN:[1495..1497] in)
                  (NP
                    (NP
                      (NP (DT:[1498..1501] the) (NN:[1502..1511] formation))
                      (CONJP (CC:[1512..1515] and) (CC:[1517..1519] or))
                      (NP (NN:[1520..1526] growth)))
                    (PP (IN:[1527..1529] of)
                      (NP (JJ:[1530..1539] pituitary)
                          (NNS:[1540..1550] metastases)))))))))))
    (.:[1550..1551] .)))

;sentence 10 Span:1552..1690
;This observed genomic instability will be of  value in predicting the
;potential metastatic behavior of these aggressive  pituitary tumors.
;[1661..1689]:malignancy:"aggressive  pituitary tumors"
(SENT
  (S
    (NP-SBJ (DT:[1552..1556] This) (JJ:[1557..1565] observed)
            (JJ:[1566..1573] genomic) (NN:[1574..1585] instability))
    (VP (MD:[1586..1590] will)
      (VP (VB:[1591..1593] be)
        (PP-PRD (IN:[1594..1596] of)
          (NP (NN:[1598..1603] value)))
        (PP (IN:[1604..1606] in)
          (S-NOM
            (NP-SBJ (-NONE-:[1606..1606] *))
            (VP (VBG:[1607..1617] predicting)
              (NP
                (NP (DT:[1618..1621] the) (JJ:[1622..1631] potential)
                    (JJ:[1632..1642] metastatic) (NN:[1643..1651] behavior))
                (PP (IN:[1652..1654] of)
                  (NP (DT:[1655..1660] these)
                     (JJ:[1661..1671] aggressive) (JJ:[1673..1682] pituitary)
                     (NNS:[1683..1689] tumors)))))))))
    (.:[1689..1690] .)))

;section 11 Span:1694..1738
;PMID: 8157709 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1694..1698] PMID) (::[1698..1699] :) (CD:[1700..1707] 8157709)
        (NN:[1708..1709] -LSB-) (NNP:[1709..1715] PubMed) (::[1716..1717] -)
        (NN:[1718..1725] indexed) (IN:[1726..1729] for)
        (NNP:[1730..1738] MEDLINE-RSB-)))
